Cytochroma strikes first major commercial alliance
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharmahas acquired rights to develop, manufacture and market in the US and Asia, including Japan, Cytochroma's vitamin D analogue for chronic kidney disease (CKD) CTA018, in a deal worth up to Cdn$105 million ($103 million) before royalties to the private Canadian firm.